Arcutis Biotherapeutics, Inc.
ARQT
$20.69
-$0.55-2.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.30M | 17.40M | 7.41M | -15.89M | -25.06M |
| Total Depreciation and Amortization | 562.00K | 563.00K | 562.00K | 410.00K | 2.98M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.18M | 10.55M | 10.22M | 10.67M | 9.39M |
| Change in Net Operating Assets | 1.79M | -2.33M | -19.94M | 5.13M | -17.69M |
| Cash from Operations | 2.24M | 26.19M | -1.75M | 324.00K | -30.38M |
| Capital Expenditure | -- | 0.00 | 0.00 | -78.00K | -608.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -11.33M | -34.18M | -25.25M | 17.50M | 12.36M |
| Cash from Investing | -11.33M | -34.18M | -25.25M | 17.42M | 11.75M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.07M | 3.72M | 1.48M | 1.38M | 395.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.07M | 3.72M | 1.48M | 1.38M | 395.00K |
| Foreign Exchange rate Adjustments | -119.00K | 59.00K | -95.00K | 200.00K | 4.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.15M | -4.21M | -25.62M | 19.33M | -18.23M |